An innovative approach to involve patients in measuring treatment effects in drug trials

Kaduszkiewicz, Hanna
April 2006
CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1117
Academic Journal
The article comments on the results of a randomized controlled double-blind trial of the cholinesterase inhibitor galantamine conducted by Rockwood et al. The trial was made for patients with Alzheimer's disease. The procedures for conducting the study are presented. The use of the Goal Attainment Scaling instrument in the study is cited. In addition, this article reveals the efficacy of galantamine in the treatment of mild to moderate Alzheimer's disease.


Related Articles

  • Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. Rockwood, Kenneth; Fay, Sherri; Xiaowei Song; MacKnight, Chris; Gorman, Mary // CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1099 

    Background: Although cholinesterase inhibitors have produced statistically significant treatment effects, their clinical meaningfulness in Alzheimer's disease is disputed. An important aspect of clinical meaningfulness is the extent to which an intervention meets the goals of treatment. Methods:...

  • Treatment of Alzheimer Disease: The Past, the Present, and the Future. Gauthie, Serge // Canadian Journal of Psychiatry;Oct2011, Vol. 56 Issue 10, p577 

    The author reflects on the treatment of the Alzheimer disease. He states that when cholinesterase inhibitor (ChEIs) first became available, family doctors were allowed to prescribe these medications and they are following evidence-based guidelines for diagnosis and treatment common to all...

  • galantamine.  // Royal Society of Medicine: Medicines;2002, p261 

    The article presents information on galantamine. The drug is an anticholinesterase recently introduced for the symptomatic treatment of mild to moderate dementia of Alzheimer's disease. It is thought only to slow the rate of cognitive deterioration in about half of patients treated. Authorities...

  • EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. Kogan, E. A.; Korczyn, A. D.; Virchovsky, R. G.; Klimovizky, S. Sh.; Treves, T. A.; Neufeld, M. Y. // Journal of Neural Transmission;Oct2001, Vol. 108 Issue 10, p1167 

    Summary. In this pilot study, we examined the long-term treatment effect of donepezil on the quantitative EEG (qEEG) in 12 Alzheimer's disease patients. The qEEGs of the mean absolute and relative amplitudes of betal, alpha, theta and delta activities were obtained at baseline and during...

  • Commentary. Gilley, David W. // Evidence Based Mental Health;Feb2006, Vol. 9 Issue 1, p19 

    The article reports on the results of a study showing that cholinesterase inhibitors provide little benefits for informal carers of community dwelling people with Alzheimer's disease. Cholinesterase inhibitors increase synaptic levels of acetylcholine and produce modest improvements in symptoms...

  • 7-Methoxytacrine-Adamantylamine Heterodimers as Cholinesterase Inhibitors in Alzheimer's Disease Treatment -- Synthesis, Biological Evaluation and Molecular Modeling Studies. Spilovska, Katarina; Korabecny, Jan; Kral, Jan; Horova, Anna; Musilek, Kamil; Soukup, Ondrej; Drtinova, Lucie; Gazova, Zuzana; Siposova, Katarina; Kuca, Kamil // Molecules;Feb2013, Vol. 18 Issue 2, p2397 

    A structural series of 7-MEOTA-adamantylamine thioureas was designed, synthesized and evaluated as inhibitors of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE). The compounds were prepared based on the multi-target-directed ligand strategy with different linker...

  • Cholinesterase inhibitors and cardiac arrhythmias.  // WHO Drug Information;2004, Vol. 18 Issue 4, p273 

    Focuses on the usage of cholinesterase inhibitors for the treatment of Alzheimer's disease. Presentation of cardiac arrhythmias and other effects with cholinesterase inhibitors; Awareness of the prescribers of the potential for cardiac arrhythmias, particularly bradycardia with cholinesterase...

  • donepezil.  // Royal Society of Medicine: Medicines;2002, p214 

    This article presents information on the anticholinesterase donepezil used for the symptomatic treatment of mild to moderate dementia of Alzheimer's disease. It is thought only to slow the rate of cognitive deterioration in about half of patients treated. Authorities have identified those...

  • A 2-Year Prospective Cohort Study of Antidementia Drug Non-Persistency in Mild-to-Moderate Alzheimer's Disease in Europe. Gardette, Virginie; Lapeyre-Mestre, Maryse; Piau, Antoine; Gallini, Adeline; Cantet, Christelle; Montastruc, Jean-Louis; Vellas, Bruno; Andrieu, Sandrine // CNS Drugs;Feb2014, Vol. 28 Issue 2, p157 

    Background: There is no consensus on when and how to discontinue cholinesterase inhibitors (ChEI). Predictors of non-persistency of antidementia drugs have been poorly investigated, mostly during short-term periods and using administrative data. Objective: The aim of this study was to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics